טוען...
Reassessment of Pioglitazone for Alzheimer’s Disease
Alzheimer’s disease is a quintessential ‘unmet medical need’, accounting for ∼65% of progressive cognitive impairment among the elderly, and 700,000 deaths in the United States in 2020. In 2019, the cost of caring for Alzheimer’s sufferers was $244B, not including the emotional and physical toll on...
שמור ב:
| הוצא לאור ב: | Front Neurosci |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8243371/ https://ncbi.nlm.nih.gov/pubmed/34220427 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fnins.2021.666958 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|